KLOW Blend
ALSO SOLD AS KLOW blend
See the stack breakdown →Last reviewed 2026-10-30
Our read Opinion
No trials of the combination were found. Evidence is borrowed from separate components, largely animal/laboratory work; full-length thymosin-beta-4 findings do not validate TB-500. FDA reports no human exposure data for KPV.
- Type
- Research-only / unapproved
- Regulatory status
- No FDA approval for the blend
- Compounding status
- Not allowed (blends excluded)
- FDA-approved indications
- None
- Evidence level
- Animal studies mostly
- Routes studied
- —
- WADA
- Prohibited
- Developer
- —
Claims made by researchers, companies and users. Inclusion does not mean the claim is verified.
- —Claimed to combine injury healing with gut, skin and hair support
GHK-Cu is studied in matrix remodeling; BPC-157 in preclinical repair; thymosin-beta-4 biology in cell migration. KPV has preclinical anti-inflammatory findings. Synergy is unproven.
Not a peptide: a pre-mixed blend of GHK-Cu + BPC-157 + TB-500 + KPV. No FDA approval was identified for the blend or its components as therapeutic drugs. FDA flags safety-data gaps for these ingredients.
Statuses change; check the linked primary source.
Momentum Opinion
Watch
0 news items in last 30 days
A branded mixture is not a validated repair treatment. More ingredients add unknown interactions, not demonstrated benefit.
No news yet for this peptide.
Information only. Not medical advice. Listing a compound is not an endorsement or a recommendation to obtain or use it. Ratings and "Our Take" are editorial opinion. Full disclaimer.